View Financial HealthDocCheck 배당 및 자사주 매입배당 기준 점검 3/6DocCheck 은(는) 현재 수익률이 8.62% 인 배당금 지급 회사입니다.핵심 정보8.6%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률9.0%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향95%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • May 22Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 29 May 2026. Payment date: 02 June 2026. Payout ratio is on the higher end at 95%, and the cash payout ratio is above 100%. Trailing yield: 7.6%. Within top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.7%).Declared Dividend • Apr 19Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 7.9%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is covered by earnings (65% earnings payout ratio) but not covered by cash flows (170% cash payout ratio). The dividend has increased by an average of 6.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 28% to shift the payout ratio to a potentially unsustainable range, which is more than the 11% EPS decline seen over the last 5 years.Upcoming Dividend • May 22Upcoming dividend of €0.75 per shareEligible shareholders must have bought the stock before 29 May 2025. Payment date: 02 June 2025. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (1.1%).분석 기사 • Apr 18DocCheck (ETR:AJ91) Will Pay A Larger Dividend Than Last Year At €0.75DocCheck AG ( ETR:AJ91 ) has announced that it will be increasing its periodic dividend on the 2nd of June to €0.75...Declared Dividend • Apr 17Dividend increased to €0.75Dividend of €0.75 is 50% higher than last year. Ex-date: 29th May 2025 Payment date: 2nd June 2025 Dividend yield will be 8.1%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not covered by earnings (104% earnings payout ratio). However, it is well covered by cash flows (39% cash payout ratio). The dividend has increased by an average of 3.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 15% to bring the payout ratio under control, which is more than the 11% EPS growth achieved over the last 5 years.공고 • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.모든 업데이트 보기Recent updatesUpcoming Dividend • May 22Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 29 May 2026. Payment date: 02 June 2026. Payout ratio is on the higher end at 95%, and the cash payout ratio is above 100%. Trailing yield: 7.6%. Within top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.7%).Valuation Update With 7 Day Price Move • May 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €14.70, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 29x in the Healthcare Services industry in Europe. Total returns to shareholders of 49% over the past three years.Buy Or Sell Opportunity • Apr 28Now 21% overvaluedOver the last 90 days, the stock has fallen 2.3% to €13.00. The fair value is estimated to be €10.77, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Declared Dividend • Apr 19Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 7.9%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is covered by earnings (65% earnings payout ratio) but not covered by cash flows (170% cash payout ratio). The dividend has increased by an average of 6.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 28% to shift the payout ratio to a potentially unsustainable range, which is more than the 11% EPS decline seen over the last 5 years.공고 • Apr 17+ 1 more updateDocCheck AG, Annual General Meeting, May 28, 2026DocCheck AG, Annual General Meeting, May 28, 2026, at 09:30 W. Europe Standard Time.Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 2.3% to €12.50. The fair value is estimated to be €10.40, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Reported Earnings • Apr 12Full year 2025 earnings released: EPS: €1.05 (vs €1.04 in FY 2024)Full year 2025 results: EPS: €1.05 (up from €1.04 in FY 2024). Revenue: €56.6m (up 5.2% from FY 2024). Net income: €5.33m (up 1.0% from FY 2024). Profit margin: 9.4% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 1% per year.Upcoming Dividend • May 22Upcoming dividend of €0.75 per shareEligible shareholders must have bought the stock before 29 May 2025. Payment date: 02 June 2025. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (1.1%).분석 기사 • May 22Shareholders May Be Wary Of Increasing DocCheck AG's (ETR:AJ91) CEO Compensation PackageKey Insights DocCheck to hold its Annual General Meeting on 28th of May Total pay for CEO Frank Antwerpes includes...분석 기사 • May 10There's No Escaping DocCheck AG's (ETR:AJ91) Muted Earnings Despite A 25% Share Price RiseDocCheck AG ( ETR:AJ91 ) shares have continued their recent momentum with a 25% gain in the last month alone. The last...분석 기사 • Apr 18DocCheck (ETR:AJ91) Will Pay A Larger Dividend Than Last Year At €0.75DocCheck AG ( ETR:AJ91 ) has announced that it will be increasing its periodic dividend on the 2nd of June to €0.75...Declared Dividend • Apr 17Dividend increased to €0.75Dividend of €0.75 is 50% higher than last year. Ex-date: 29th May 2025 Payment date: 2nd June 2025 Dividend yield will be 8.1%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not covered by earnings (104% earnings payout ratio). However, it is well covered by cash flows (39% cash payout ratio). The dividend has increased by an average of 3.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 15% to bring the payout ratio under control, which is more than the 11% EPS growth achieved over the last 5 years.공고 • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.Reported Earnings • Apr 13Full year 2024 earnings released: EPS: €1.04 (vs €0.45 in FY 2023)Full year 2024 results: EPS: €1.04 (up from €0.45 in FY 2023). Revenue: €54.6m (up 2.3% from FY 2023). Net income: €5.28m (up 133% from FY 2023). Profit margin: 9.7% (up from 4.3% in FY 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.3% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Share price has been volatile over the past 3 months (7.0% average weekly change). Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (€57.8m market cap, or US$60.7m).Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €10.10, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 27x in the Healthcare Services industry in Europe. Total loss to shareholders of 53% over the past three years.분석 기사 • Nov 19DocCheck's (ETR:AJ91) Returns On Capital Not Reflecting Well On The BusinessIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Reported Earnings • Sep 26First half 2024 earnings released: EPS: €0.37 (vs €0.34 in 1H 2023)First half 2024 results: EPS: €0.37 (up from €0.34 in 1H 2023). Revenue: €24.4m (down 6.8% from 1H 2023). Net income: €1.87m (up 10% from 1H 2023). Profit margin: 7.7% (up from 6.5% in 1H 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.New Risk • Sep 26New major risk - Revenue and earnings growthEarnings have declined by 4.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.3% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (€37.8m market cap, or US$42.1m).Upcoming Dividend • May 23Upcoming dividend of €0.50 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 03 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.5%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.6%).분석 기사 • Apr 19We Think You Can Look Beyond DocCheck's (ETR:AJ91) Lackluster EarningsSoft earnings didn't appear to concern DocCheck AG's ( ETR:AJ91 ) shareholders over the last week. We think that the...Reported Earnings • Apr 17Full year 2023 earnings released: EPS: €0.45 (vs €1.25 in FY 2022)Full year 2023 results: EPS: €0.45 (down from €1.25 in FY 2022). Revenue: €53.4m (down 12% from FY 2022). Net income: €2.27m (down 64% from FY 2022). Profit margin: 4.3% (down from 10% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€45.7m market cap, or US$48.6m).Reported Earnings • Oct 05First half 2023 earnings released: EPS: €0.34 (vs €0.42 in 1H 2022)First half 2023 results: EPS: €0.34 (down from €0.42 in 1H 2022). Revenue: €26.2m (down 11% from 1H 2022). Net income: €1.70m (down 19% from 1H 2022). Profit margin: 6.5% (down from 7.1% in 1H 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.분석 기사 • Aug 04DocCheck (ETR:AJ91) Has Some Way To Go To Become A Multi-BaggerFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (34% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (€53.4m market cap, or US$58.8m).Upcoming Dividend • May 25Upcoming dividend of €0.75 per share at 5.8% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €13.40, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 24x in the Healthcare Services industry in Germany. Total returns to shareholders of 48% over the past three years.분석 기사 • May 20Estimating The Fair Value Of DocCheck AG (ETR:AJ91)Key Insights Using the Dividend Discount Model, DocCheck fair value estimate is €12.66 DocCheck's €13.40 share price...Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 16% share price gain to €15.05, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 26x in the Healthcare Services industry in Germany. Total returns to shareholders of 78% over the past three years.분석 기사 • Nov 06The Trend Of High Returns At DocCheck (ETR:AJ91) Has Us Very InterestedIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improved over the past weekAfter last week's 21% share price gain to €15.25, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 23x in the Healthcare Services industry in Germany. Total returns to shareholders of 78% over the past three years.Upcoming Dividend • May 25Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 01 June 2022. Payment date: 03 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.3%).Buying Opportunity • May 20Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 27%. The fair value is estimated to be €23.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has grown by 61%.Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €2.27 (vs €1.83 in FY 2020)Full year 2021 results: EPS: €2.27 (up from €1.83 in FY 2020). Revenue: €86.4m (up 37% from FY 2020). Net income: €11.4m (up 24% from FY 2020). Profit margin: 13% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €20.40, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 37x in the Healthcare Services industry in Germany. Total returns to shareholders of 181% over the past three years.분석 기사 • Mar 03Returns On Capital Are A Standout For DocCheck (ETR:AJ91)To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...분석 기사 • Jan 18If You Like EPS Growth Then Check Out DocCheck (ETR:AJ91) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 21% share price gain to €30.90, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 55x in the Healthcare Services industry in Germany. Total returns to shareholders of 294% over the past three years.분석 기사 • Aug 26Do DocCheck's (ETR:AJ91) Earnings Warrant Your Attention?Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Upcoming Dividend • May 24Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 31 May 2021. Payment date: 02 June 2021. Trailing yield: 3.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.1%).분석 기사 • May 02Should DocCheck AG (ETR:AJ91) Be Part Of Your Dividend Portfolio?Today we'll take a closer look at DocCheck AG ( ETR:AJ91 ) from a dividend investor's perspective. Owning a strong...Reported Earnings • Apr 18Full year 2020 earnings released: EPS €1.83 (vs €0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €63.7m (up 97% from FY 2019). Net income: €9.20m (up 193% from FY 2019). Profit margin: 14% (up from 9.7% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.분석 기사 • Apr 18Investors Shouldn't Overlook DocCheck's (ETR:AJ91) Impressive Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...Valuation Update With 7 Day Price Move • Apr 03Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €24.30, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 51x in the Healthcare Services industry in Germany. Total returns to shareholders of 154% over the past three years.분석 기사 • Mar 23Should You Be Adding DocCheck (ETR:AJ91) To Your Watchlist Today?It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...분석 기사 • Mar 04Is DocCheck AG's (ETR:AJ91) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?DocCheck (ETR:AJ91) has had a great run on the share market with its stock up by a significant 25% over the last month...Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €25.80, the stock is trading at a trailing P/E ratio of 29.9x, down from the previous P/E ratio of 35.4x. This compares to an average P/E of 48x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 150%.분석 기사 • Feb 14Did You Participate In Any Of DocCheck's (ETR:AJ91) Incredible 419% Return?For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly...Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 18% share price gain to €26.80, the stock is trading at a trailing P/E ratio of 31x, up from the previous P/E ratio of 26.4x. This compares to an average P/E of 42x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 182%.Is New 90 Day High Low • Feb 06New 90-day high: €26.80The company is up 57% from its price of €17.10 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 1.0% over the same period.분석 기사 • Jan 27Could The DocCheck AG (ETR:AJ91) Ownership Structure Tell Us Something Useful?If you want to know who really controls DocCheck AG ( ETR:AJ91 ), then you'll have to look at the makeup of its share...분석 기사 • Jan 10Under The Bonnet, DocCheck's (ETR:AJ91) Returns Look ImpressiveWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Is New 90 Day High Low • Jan 06New 90-day high: €24.60The company is up 51% from its price of €16.30 on 08 October 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period.분석 기사 • Dec 22If You Like EPS Growth Then Check Out DocCheck (ETR:AJ91) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...분석 기사 • Dec 07What Can We Conclude About DocCheck's (ETR:AJ91) CEO Pay?The CEO of DocCheck AG ( ETR:AJ91 ) is Frank Antwerpes, and this article examines the executive's compensation against...분석 기사 • Nov 22DocCheck AG's (ETR:AJ91) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?DocCheck (ETR:AJ91) has had a great run on the share market with its stock up by a significant 56% over the last three...Is New 90 Day High Low • Nov 11New 90-day high: €21.80The company is up 59% from its price of €13.70 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period.Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 29% share price gain to €21.80, the stock is trading at a trailing P/E ratio of 25.2x, up from the previous P/E ratio of 19.6x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 147%.Is New 90 Day High Low • Oct 08New 90-day high: €16.30The company is up 55% from its price of €10.50 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period.공고 • Jul 31DocCheck AG (XTRA:AJ91) acquired MediShopXL.DocCheck AG (XTRA:AJ91) acquired MediShopXL in the first quarter of 2020. DocCheck AG (XTRA:AJ91) completed the acquisition of MediShopXL in the first quarter of 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: AJ91 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: AJ91 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장DocCheck 배당 수익률 vs 시장AJ91의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (AJ91)8.6%시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Healthcare Services)1.8%분석가 예측 (AJ91) (최대 3년)n/a주목할만한 배당금: AJ91 의 배당금( 8.62% )은 German 시장에서 배당금 지급자의 하위 25%( 1.54% )보다 높습니다.고배당: AJ91 의 배당금( 8.62% )은 German 시장( 4.69% )주주 대상 이익 배당수익 보장: 지급 비율 ( 95.1% )이 높기 때문에 AJ91 의 배당금 지급은 수익으로 잘 충당되지 않습니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 226.7% )이 높기 때문에 AJ91 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/31 00:25종가2026/07/31 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스DocCheck AG는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Upcoming Dividend • May 22Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 29 May 2026. Payment date: 02 June 2026. Payout ratio is on the higher end at 95%, and the cash payout ratio is above 100%. Trailing yield: 7.6%. Within top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.7%).
Declared Dividend • Apr 19Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 7.9%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is covered by earnings (65% earnings payout ratio) but not covered by cash flows (170% cash payout ratio). The dividend has increased by an average of 6.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 28% to shift the payout ratio to a potentially unsustainable range, which is more than the 11% EPS decline seen over the last 5 years.
Upcoming Dividend • May 22Upcoming dividend of €0.75 per shareEligible shareholders must have bought the stock before 29 May 2025. Payment date: 02 June 2025. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (1.1%).
분석 기사 • Apr 18DocCheck (ETR:AJ91) Will Pay A Larger Dividend Than Last Year At €0.75DocCheck AG ( ETR:AJ91 ) has announced that it will be increasing its periodic dividend on the 2nd of June to €0.75...
Declared Dividend • Apr 17Dividend increased to €0.75Dividend of €0.75 is 50% higher than last year. Ex-date: 29th May 2025 Payment date: 2nd June 2025 Dividend yield will be 8.1%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not covered by earnings (104% earnings payout ratio). However, it is well covered by cash flows (39% cash payout ratio). The dividend has increased by an average of 3.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 15% to bring the payout ratio under control, which is more than the 11% EPS growth achieved over the last 5 years.
공고 • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.
Upcoming Dividend • May 22Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 29 May 2026. Payment date: 02 June 2026. Payout ratio is on the higher end at 95%, and the cash payout ratio is above 100%. Trailing yield: 7.6%. Within top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.7%).
Valuation Update With 7 Day Price Move • May 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €14.70, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 29x in the Healthcare Services industry in Europe. Total returns to shareholders of 49% over the past three years.
Buy Or Sell Opportunity • Apr 28Now 21% overvaluedOver the last 90 days, the stock has fallen 2.3% to €13.00. The fair value is estimated to be €10.77, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Declared Dividend • Apr 19Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 7.9%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is covered by earnings (65% earnings payout ratio) but not covered by cash flows (170% cash payout ratio). The dividend has increased by an average of 6.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 28% to shift the payout ratio to a potentially unsustainable range, which is more than the 11% EPS decline seen over the last 5 years.
공고 • Apr 17+ 1 more updateDocCheck AG, Annual General Meeting, May 28, 2026DocCheck AG, Annual General Meeting, May 28, 2026, at 09:30 W. Europe Standard Time.
Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 2.3% to €12.50. The fair value is estimated to be €10.40, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Reported Earnings • Apr 12Full year 2025 earnings released: EPS: €1.05 (vs €1.04 in FY 2024)Full year 2025 results: EPS: €1.05 (up from €1.04 in FY 2024). Revenue: €56.6m (up 5.2% from FY 2024). Net income: €5.33m (up 1.0% from FY 2024). Profit margin: 9.4% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 1% per year.
Upcoming Dividend • May 22Upcoming dividend of €0.75 per shareEligible shareholders must have bought the stock before 29 May 2025. Payment date: 02 June 2025. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (1.1%).
분석 기사 • May 22Shareholders May Be Wary Of Increasing DocCheck AG's (ETR:AJ91) CEO Compensation PackageKey Insights DocCheck to hold its Annual General Meeting on 28th of May Total pay for CEO Frank Antwerpes includes...
분석 기사 • May 10There's No Escaping DocCheck AG's (ETR:AJ91) Muted Earnings Despite A 25% Share Price RiseDocCheck AG ( ETR:AJ91 ) shares have continued their recent momentum with a 25% gain in the last month alone. The last...
분석 기사 • Apr 18DocCheck (ETR:AJ91) Will Pay A Larger Dividend Than Last Year At €0.75DocCheck AG ( ETR:AJ91 ) has announced that it will be increasing its periodic dividend on the 2nd of June to €0.75...
Declared Dividend • Apr 17Dividend increased to €0.75Dividend of €0.75 is 50% higher than last year. Ex-date: 29th May 2025 Payment date: 2nd June 2025 Dividend yield will be 8.1%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not covered by earnings (104% earnings payout ratio). However, it is well covered by cash flows (39% cash payout ratio). The dividend has increased by an average of 3.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 15% to bring the payout ratio under control, which is more than the 11% EPS growth achieved over the last 5 years.
공고 • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.
Reported Earnings • Apr 13Full year 2024 earnings released: EPS: €1.04 (vs €0.45 in FY 2023)Full year 2024 results: EPS: €1.04 (up from €0.45 in FY 2023). Revenue: €54.6m (up 2.3% from FY 2023). Net income: €5.28m (up 133% from FY 2023). Profit margin: 9.7% (up from 4.3% in FY 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.3% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Share price has been volatile over the past 3 months (7.0% average weekly change). Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (€57.8m market cap, or US$60.7m).
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €10.10, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 27x in the Healthcare Services industry in Europe. Total loss to shareholders of 53% over the past three years.
분석 기사 • Nov 19DocCheck's (ETR:AJ91) Returns On Capital Not Reflecting Well On The BusinessIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Reported Earnings • Sep 26First half 2024 earnings released: EPS: €0.37 (vs €0.34 in 1H 2023)First half 2024 results: EPS: €0.37 (up from €0.34 in 1H 2023). Revenue: €24.4m (down 6.8% from 1H 2023). Net income: €1.87m (up 10% from 1H 2023). Profit margin: 7.7% (up from 6.5% in 1H 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
New Risk • Sep 26New major risk - Revenue and earnings growthEarnings have declined by 4.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.3% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (€37.8m market cap, or US$42.1m).
Upcoming Dividend • May 23Upcoming dividend of €0.50 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 03 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.5%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.6%).
분석 기사 • Apr 19We Think You Can Look Beyond DocCheck's (ETR:AJ91) Lackluster EarningsSoft earnings didn't appear to concern DocCheck AG's ( ETR:AJ91 ) shareholders over the last week. We think that the...
Reported Earnings • Apr 17Full year 2023 earnings released: EPS: €0.45 (vs €1.25 in FY 2022)Full year 2023 results: EPS: €0.45 (down from €1.25 in FY 2022). Revenue: €53.4m (down 12% from FY 2022). Net income: €2.27m (down 64% from FY 2022). Profit margin: 4.3% (down from 10% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€45.7m market cap, or US$48.6m).
Reported Earnings • Oct 05First half 2023 earnings released: EPS: €0.34 (vs €0.42 in 1H 2022)First half 2023 results: EPS: €0.34 (down from €0.42 in 1H 2022). Revenue: €26.2m (down 11% from 1H 2022). Net income: €1.70m (down 19% from 1H 2022). Profit margin: 6.5% (down from 7.1% in 1H 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
분석 기사 • Aug 04DocCheck (ETR:AJ91) Has Some Way To Go To Become A Multi-BaggerFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (34% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (€53.4m market cap, or US$58.8m).
Upcoming Dividend • May 25Upcoming dividend of €0.75 per share at 5.8% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €13.40, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 24x in the Healthcare Services industry in Germany. Total returns to shareholders of 48% over the past three years.
분석 기사 • May 20Estimating The Fair Value Of DocCheck AG (ETR:AJ91)Key Insights Using the Dividend Discount Model, DocCheck fair value estimate is €12.66 DocCheck's €13.40 share price...
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 16% share price gain to €15.05, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 26x in the Healthcare Services industry in Germany. Total returns to shareholders of 78% over the past three years.
분석 기사 • Nov 06The Trend Of High Returns At DocCheck (ETR:AJ91) Has Us Very InterestedIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improved over the past weekAfter last week's 21% share price gain to €15.25, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 23x in the Healthcare Services industry in Germany. Total returns to shareholders of 78% over the past three years.
Upcoming Dividend • May 25Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 01 June 2022. Payment date: 03 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.3%).
Buying Opportunity • May 20Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 27%. The fair value is estimated to be €23.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has grown by 61%.
Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €2.27 (vs €1.83 in FY 2020)Full year 2021 results: EPS: €2.27 (up from €1.83 in FY 2020). Revenue: €86.4m (up 37% from FY 2020). Net income: €11.4m (up 24% from FY 2020). Profit margin: 13% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €20.40, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 37x in the Healthcare Services industry in Germany. Total returns to shareholders of 181% over the past three years.
분석 기사 • Mar 03Returns On Capital Are A Standout For DocCheck (ETR:AJ91)To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
분석 기사 • Jan 18If You Like EPS Growth Then Check Out DocCheck (ETR:AJ91) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 21% share price gain to €30.90, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 55x in the Healthcare Services industry in Germany. Total returns to shareholders of 294% over the past three years.
분석 기사 • Aug 26Do DocCheck's (ETR:AJ91) Earnings Warrant Your Attention?Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Upcoming Dividend • May 24Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 31 May 2021. Payment date: 02 June 2021. Trailing yield: 3.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.1%).
분석 기사 • May 02Should DocCheck AG (ETR:AJ91) Be Part Of Your Dividend Portfolio?Today we'll take a closer look at DocCheck AG ( ETR:AJ91 ) from a dividend investor's perspective. Owning a strong...
Reported Earnings • Apr 18Full year 2020 earnings released: EPS €1.83 (vs €0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €63.7m (up 97% from FY 2019). Net income: €9.20m (up 193% from FY 2019). Profit margin: 14% (up from 9.7% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
분석 기사 • Apr 18Investors Shouldn't Overlook DocCheck's (ETR:AJ91) Impressive Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €24.30, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 51x in the Healthcare Services industry in Germany. Total returns to shareholders of 154% over the past three years.
분석 기사 • Mar 23Should You Be Adding DocCheck (ETR:AJ91) To Your Watchlist Today?It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
분석 기사 • Mar 04Is DocCheck AG's (ETR:AJ91) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?DocCheck (ETR:AJ91) has had a great run on the share market with its stock up by a significant 25% over the last month...
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €25.80, the stock is trading at a trailing P/E ratio of 29.9x, down from the previous P/E ratio of 35.4x. This compares to an average P/E of 48x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 150%.
분석 기사 • Feb 14Did You Participate In Any Of DocCheck's (ETR:AJ91) Incredible 419% Return?For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly...
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 18% share price gain to €26.80, the stock is trading at a trailing P/E ratio of 31x, up from the previous P/E ratio of 26.4x. This compares to an average P/E of 42x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 182%.
Is New 90 Day High Low • Feb 06New 90-day high: €26.80The company is up 57% from its price of €17.10 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 1.0% over the same period.
분석 기사 • Jan 27Could The DocCheck AG (ETR:AJ91) Ownership Structure Tell Us Something Useful?If you want to know who really controls DocCheck AG ( ETR:AJ91 ), then you'll have to look at the makeup of its share...
분석 기사 • Jan 10Under The Bonnet, DocCheck's (ETR:AJ91) Returns Look ImpressiveWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Is New 90 Day High Low • Jan 06New 90-day high: €24.60The company is up 51% from its price of €16.30 on 08 October 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period.
분석 기사 • Dec 22If You Like EPS Growth Then Check Out DocCheck (ETR:AJ91) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
분석 기사 • Dec 07What Can We Conclude About DocCheck's (ETR:AJ91) CEO Pay?The CEO of DocCheck AG ( ETR:AJ91 ) is Frank Antwerpes, and this article examines the executive's compensation against...
분석 기사 • Nov 22DocCheck AG's (ETR:AJ91) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?DocCheck (ETR:AJ91) has had a great run on the share market with its stock up by a significant 56% over the last three...
Is New 90 Day High Low • Nov 11New 90-day high: €21.80The company is up 59% from its price of €13.70 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period.
Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 29% share price gain to €21.80, the stock is trading at a trailing P/E ratio of 25.2x, up from the previous P/E ratio of 19.6x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 147%.
Is New 90 Day High Low • Oct 08New 90-day high: €16.30The company is up 55% from its price of €10.50 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period.
공고 • Jul 31DocCheck AG (XTRA:AJ91) acquired MediShopXL.DocCheck AG (XTRA:AJ91) acquired MediShopXL in the first quarter of 2020. DocCheck AG (XTRA:AJ91) completed the acquisition of MediShopXL in the first quarter of 2020.